Issue 1, 2021

Nuclear delivery of dual anti-cancer drugs by molecular self-assembly

Abstract

Nanomedicines generally suffer from poor accumulation in tumor cells, low anti-tumor efficacy, and drug resistance. In order to address these problems, we introduced a novel nanomedicine based on dual anti-cancer drugs, which showed good cell nuclear accumulation properties. The novel nanomedicine consisted of three components: (1) dual anti-cancer drugs, 10-hydroxycamptothecin (HCPT) and chlorambucil (CRB), whose targets are located in the cell nucleus, (2) a nuclear localizing dodecapeptide, PMI peptide (TSFAEYWNLLSP), which could activate p53 by binding with MDM2 and MDMX located in the cell nucleus, and (3) an efficient self-assembling tripeptide FFY. Our nanomedicine exhibited enhanced cellular uptake and nuclear accumulation properties, thus achieving an excellent anti-cancer capacity both in vitro and in vivo. Our study will provide an inspiration for the development of novel multifunctional nanomaterials for cancer diagnosis and therapy.

Graphical abstract: Nuclear delivery of dual anti-cancer drugs by molecular self-assembly

Supplementary files

Article information

Article type
Paper
Submitted
13 Jun 2020
Accepted
03 Aug 2020
First published
07 Sep 2020

Biomater. Sci., 2021,9, 116-123

Nuclear delivery of dual anti-cancer drugs by molecular self-assembly

J. Wu, W. Ding, G. Han, W. You, W. Gao, H. Shen, J. Tang, Q. Tang and X. Wang, Biomater. Sci., 2021, 9, 116 DOI: 10.1039/D0BM00971G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements